H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report)’s stock price traded down 49.5% during mid-day trading on Thursday. The stock traded as low as $2.02 and last traded at $2.02. Approximately 400 shares were traded during mid-day trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Trading Down 49.5%
The stock’s fifty day moving average price is $2.02 and its 200-day moving average price is $2.02.
H-CYTE Company Profile
H-Cyte, Inc is a clinical-stage biotechnology company focused on developing regenerative cell therapies for chronic pulmonary and respiratory diseases. Its primary investigational product, H-Cyte therapy, is designed to use a patient’s own cells in an effort to support lung repair and improve respiratory function.
The company has focused its research and development activities on conditions such as chronic obstructive pulmonary disease, emphysema and other serious lung disorders. H-Cyte’s therapies remain investigational, and their safety and effectiveness depend on the results of clinical development and regulatory review.
H-Cyte is based in the United States and has pursued clinical and commercial development of its cell-based technology for patients with significant respiratory disease.
Featured Articles
- Five stocks we like better than H-CYTE
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}